286 related articles for article (PubMed ID: 28429679)
1. Mycobacterium avium Complex Disease.
Daley CL
Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28429679
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit assessment of therapies for Mycobacterium avium complex infections.
Griffith DE
Drug Saf; 1999 Aug; 21(2):137-52. PubMed ID: 10456381
[TBL] [Abstract][Full Text] [Related]
3. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
4. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease.
Jeong BH; Jeon K; Park HY; Moon SM; Kim SY; Lee SY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):6076-83. PubMed ID: 27480854
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of infections due to Mycobacterium avium complex.
Kasperbauer SH; Daley CL
Semin Respir Crit Care Med; 2008 Oct; 29(5):569-76. PubMed ID: 18810690
[TBL] [Abstract][Full Text] [Related]
6. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Lee JH; Park YE; Chong YP; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.
Griffith DE; Brown BA; Girard WM; Griffith BE; Couch LA; Wallace RJ
Clin Infect Dis; 2001 Jun; 32(11):1547-53. PubMed ID: 11340525
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
11. Controversies in the management of Mycobacterium avium complex infection in AIDS patients.
Peloquin CA
Ann Pharmacother; 1993; 27(7-8):928-37. PubMed ID: 8364280
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.
Peloquin CA
Clin Pharmacokinet; 1997 Feb; 32(2):132-44. PubMed ID: 9068928
[TBL] [Abstract][Full Text] [Related]
13. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
15. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
Nguyen MH; Daley CL
Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
19. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA
Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
